GVR Report cover Rabies Veterinary Vaccines Market Size, Share & Trends Report

Rabies Veterinary Vaccines Market Size, Share & Trends Analysis Report By Application (Companion Animals, Livestock Animals, Wildlife Animals), By Region, And Segment Forecasts, 2023 - 2030

  • Report ID: GVR-4-68040-011-9
  • Number of Pages: 150
  • Format: Electronic (PDF)
  • Historical Range: 2018 - 2021
  • Industry: Healthcare

Report Overview

The global rabies veterinary vaccines market size was valued at USD 584.8 million in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 4.1% from 2023 to 2030. The market growth is propelled by factors such as the rise in animal rabies vaccination coverage in developing countries, an increase in awareness regarding zoonotic diseases, growing government initiatives to eradicate animal rabies, nationwide and countrywide implementation of mass dog vaccination campaigns, rising wildlife rabies-eradication bait programs, and significant growth of pet ownership rates.

 U.S. rabies veterinary vaccines market size, by application, 2020 - 2030 (USD Million)

The most common way of this viral transmission is by the bite of a rabid animal to other domestic animals or humans. Rabies is a dangerous but preventable viral disease; however, in most cases without timely preventive or treatment measures, rabies virus affects animals' central nervous systems, ultimately leading to brain inflammation and death. According to a National Foundation for Infectious Diseases article, nearly 5,000 rabies cases in animals are reported in the U.S. each year, with over 90% of the cases occurring in wildlife, whereas domestic animals such as dogs and cats account for approximately 10% of animal rabies incidents.

Rabies is a dangerous and frequently fatal infection in any species. In developed countries such as the U.S. and Canada, the majority of rabies cases transmitted to humans, pets, and other domestic species are caused by rabid wild animals, including raccoons, skunks, foxes, and bats. In such countries, rabies has also been observed to infect horses, swine, and cattle. On the other hand, throughout a large portion of the rest of the world, including Africa, Asia, and Latin America, most cases of rabies transmission are caused by dogs. The fight to eradicate canine rabies in Latin America has made great advances in recent years. Constant and intense surveillance of rabid dogs and yearly mass dog vaccination campaigns have been key components of Latin America's rabies prevention programs, which lead to successful results. However, such rabies eradication and prevention initiatives have been threatened as a result of crucial attempts to control COVID-19 in several regions.

The provision of rabies vaccinations to domesticated animals such as dogs, cats, and ferrets is strictly regulated in the majority of countries. Only licensed veterinarians are permitted to give the vaccine, although some regions also let veterinary technicians and people with specialized training immunize these animals. State-by-state variations exist in the frequency of rabies vaccine requirements. Some states specify a time period, while others adhere to the Compendium of Animal Rabies Prevention and Control or the product label of the utilized vaccination. Additionally, some countries are starting to grant exceptions to vaccination laws, in cases when they are medically required by a veterinarian.

The European Union's methodical approach to combating canine and wildlife-mediated rabies has demonstrated that the illness can be controlled and eliminated at the animal source. The successful oral rabies vaccination campaign for foxes and raccoon dogs, which was the result of ten years of development effort and support by the European Union, served as a model for the eradication of wildlife-mediated rabies. Over the past few years or decades, rabies was eradicated in many European nations, including almost all EU Member States, EFTA nations, the U.K., Balkan nations, and some parts of Eastern European nations. Such an improvement was made possible by the effective multiannual implementation of the vaccination of dogs and cats, oral rabies immunization of wild animals, intense passive surveillance, and coordination with stakeholders in a ‘One Health’ strategy.

Application Insights

The companion animals segment dominated the global market with a revenue share of over 65.0% in 2022. Nearly 98% of rabies transmission in several parts of the world is caused by the infected dog population. The rabies virus can incubate in any mammal for days to months without definitive clinical signs, therefore limiting the timely treatments. This devastating viral infection causes severe inflammation in the brain leading usually to death. The only way of protecting pet animals and owners is by getting a regular rabies vaccination and boosters. Considering the major impact of this zoonotic neuroinvasive infection, many countries have mandated rabies vaccination for companion animals, which supports the estimated revenue share.

The wild animals segment is anticipated to expand at the fastest CAGR of 4.4% over the forecast period owing to the rising wildlife rabies vaccination campaigns in developed regions. According to the Centers for Disease Control & Prevention, wild animals were responsible for 92.7% of U.S. rabies cases registered in 2018. Raccoons (30.3%), skunks (20.3%), foxes (7.2%), and bats (33%) were the most commonly reported wild rabid species. Variants of the rabies virus remain spread within the species to which they have been widely adopted. Similarly, raccoons, foxes, skunks, and mongooses have rabies virus variations that are concentrated in specific geographical areas.

 Global rabies veterinary vaccines market share, by application, 2022 (%)                 

For instance, in every state of the U.S. besides Hawaii, rabid bats were reported between 2013 and 2022. In some areas of California, Texas, the Midwest, Virginia, North Carolina, Kentucky, and Tennessee, rabies-carrying skunks have been commonly identified. The South and Eastern states have reported finding rabid raccoons. There have been cases of rabid foxes in Alaska, Arizona, and New Mexico. Moreover, in Texas, Arizona, and New Mexico, rabies-carrying foxes and skunks have been found; whereas, in Puerto Rico, rabies-carrying mongooses have been seen.

According to an article published by the Centers for Disease Control and Prevention, domestic dogs no longer serve as a rabies reservoir in the United States due to the implementation of mandated canine vaccination programs that have stopped the disease's natural transmission among them. Nevertheless, each year, reports of rabid animals range from 60 to 70 canines to over 250 cats. Almost all of these animals lacked vaccinations and contracted rabies from wild animals (such as bats, raccoons, and skunks).

Regional Insights

North America dominated the market with a revenue share of over 25.0% in 2022. This can be attributed to the presence of a large pet population with respectively high veterinary healthcare expenditure. In addition, well-established veterinary pharmaceutical companies and government organizations are striving for the wide implementation of mass vaccination programs and oral wildlife rabies bait-vaccine campaigns to augment rabies eradication measures. The increasing pet humanization trends and awareness among pet owners to prevent fatal infections such as rabies in their beloved animals are further improving the vaccination coverage of the region.

Rabies Veterinary Vaccines Market Trends by Region

Asia Pacific held the second-largest share in 2022 and is anticipated to grow at the fastest rate during the forecast period. Rabies is one of the major public health concerns in Southeast Asian countries. China, India, and most ASEAN countries are reported to be endemic for canine rabies with significantly higher rabies-related cases each year. The large presence of the stray dog population is a major reason for the disease burden in Asia. Recently, the region has initiated several strategies to eradicate rabies by 2030, such as the implementation of mass dog vaccination programs in collaboration with key players and government organizations. For instance, as a part of the rabies control initiative, Global Alliance for Rabies Control (GARC) and Boehringer Ingelheim have organized a mass rabies vaccination program in April 2022 to vaccinate 12,000 animals across the Philippines, Indonesia, Vietnam, and Malaysia. These factors are significantly contributing to the market growth.

Key Companies & Market Share Insights

The market is fairly competitive with the presence of several large and small players. Large companies are publicly traded and have diverse portfolios with robust R&D, distribution, and sales capabilities. Medium and small companies focus on specific solutions that cater to customer needs in the market. These include partnerships, mergers and acquisitions, R&D, regional expansion, and product launches. For instance, in June 2022, Ceva Sante Animale acquired Artemis Technologies, Inc., a Canadian oral rabies vaccine manufacturer. This acquisition expanded the company’s veterinary vaccine offerings with ONRAB, a recombinant oral vaccine that showed positive trial results for wild skunks and raccoons in the U.S. Some prominent players in the global rabies veterinary vaccines market include:

  • Merck & Co., Inc. (MSD Animal Health)

  • Indian Immunologicals Ltd.

  • Boehringer Ingelheim International GmbH (Animal Health)

  • Zoetis

  • Virbac

  • BroadChem Philippines Biopharma Corporation

  • Elanco

  • Ceva

  • BiogénesisBagó

Rabies Veterinary Vaccines Market Report Scope

Report Attribute


Market size value in 2023

USD 605.9 million

Revenue forecast in 2030

USD 802.5 million

Growth rate

CAGR of 4.1% from 2023 to 2030

Base year for estimation


Historical data

2018 - 2021

Forecast period

2023 - 2030

Quantitative units

Revenue in USD million & CAGR from 2023 to 2030

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments covered

Application, region

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; Poland; Russia; Romania; Turkey; Spain; Japan; China; India; Thailand; South Korea; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE

Key companies profiled

Merck & Co., Inc. (MSD Animal Health); Indian Immunologicals Ltd.; Boehringer Ingelheim International GmbH (Animal Health); Zoetis; Virbac; BroadChem Philippines Biopharma Corporation; Elanco, Ceva, BiogénesisBagó

Customization scope

Free report customization (equivalent up to 8 analysts’ working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options


Global Rabies Veterinary Vaccines Market Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global rabies veterinary vaccines market report on the basis of application and region:

Global Rabies Veterinary Vaccines Market Segmentation

  • Application Outlook (Revenue, USD Million, 2018 - 2030)

    • Companion Animals

    • Livestock Animals

    • Wildlife Animals

  • Regional Outlook (Revenue, USD Million, 2018 - 2030)

    • North America

      • U.S.

      • Canada

    • Europe

      • Poland

      • Russia

      • Romania

      • Turkey

      • Spain

    • Asia Pacific

      • China

      • Japan

      • India

      • South Korea

      • Thailand

    • Latin America

      • Brazil

      • Mexico

      • Argentina

    • Middle East & Africa

      • South Africa

      • South Arabia

      • UAE

Frequently Asked Questions About This Report

gvr icn


gvr icn

This FREE sample includes data points, ranging from trend analyses to estimates and forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now

Certified Icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.